Direct-acting antiviral therapy was safe and highly effective in patients coinfected with HIV and hepatitis C, according to a recently published study. Factors that negatively affected sustained virologic response rates included HIV-related immunosuppression, HCV RNA load, severity of liver disease and suboptimal DAA-based regimens.
“Concern has been raised about the generalizability of inclusion criteria from clinical trials of different DAAs to the highly heterogeneous population of HIV/HCV-coinfected patients,” Juan Berenguer, MD, PhD, from the Hospital General Universitario Gregorio Marañón, Spain, and colleagues wrote. “We evaluated the response to treatment in a large prospective registry of HIV/HCV-coinfected persons receiving DAA-based HCV therapy in the region of Madrid (Spain) and analyzed factors associated with treatment failure.”
Berenguer and colleagues prospectively followed 2,396 patients with HIV/HCV-coinfection during treatment. Median patient age was 51 years, 78.2% were men, 63.9% were treatment-naive, 803 had compensated cirrhosis and 156 had decompensated cirrhosis. Patients had HCV genotype 1a (40.9%), 1b (15.1%), 3 (15%) or 4 (22.4%).